OakChart

Neogenomics Inc

NEOHealthcare·Diagnostics & Research·USA·Mid·NASD·Nov 11 • 12:37 PM ET

16.94-0.01 (-0.09%)
2026-11-11 18:37 CET
Market cap
2,194.44 USD m
Revenue, TTM
787.75 USD m
Net income, TTM
-32.30 USD m
Free cash flow, TTM
-28.58 USD m
EPS diluted, TTM
-0.25
P/E
-
Compare

Price

NEO against its 20, 50 and 200-day averages
2050200beat
10.0015.0020.007.0M14.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NEOclose 16.9520-day 16.9850-day 17.60200-day 12.9516.9552w high

15.9% under the 52-week high of 20.15 on 6 Oct 2026. 52-week low 7.07 on 30 Mar 2026. Last 15 sessions, 14.2% high to low

Profile

NEO
52-week range, 75% of the way up
7.0720.15

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

IndexRUT
Employees2500
IPONov 10, 1999
Beta1.83
ATR, 14d0.89
Rel volume0.25
Short float10.35%
Insider own1.93%
Inst own116.52%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.19B
Enterprise Value2.50B
Income-32.30M
Sales787.75M
Book/sh6.20
Cash/sh1.08
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2500
IPONov 10, 1999

Ratios

P/E-
Forward P/E54.14
PEG1.09
P/S2.78
P/B2.73
P/C15.74
P/FCF-
EV/EBITDA133.10
EV/Sales3.18
Quick Ratio3.31
Current Ratio3.53
Debt/Eq0.56
LT Debt/Eq0.55
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.25
EPS next Y0.31
EPS next Q0.07
EPS this Y70.00%
EPS next Y53.43%
EPS next 5Y49.79%
EPS past 3/5Y10.12% -
Sales past 3/5Y12.58% 10.35%
EPS Y/Y TTM71.76%
Sales Y/Y TTM11.08%
EPS Q/Q72.22%
Sales Q/Q11.43%
EarningsOct 28 AMC
EPS/Sales Surpr.26.13% 1.23%

Ownership

Insider Own1.93%
Insider Trans-1.21%
Inst Own116.52%
Inst Trans10.55%
ROA-2.35%
ROE-3.94%
ROIC-2.60%
Gross Margin42.65%
Oper. Margin-5.89%
Profit Margin-4.10%
SMA20-0.18%
SMA50-3.71%
SMA20030.84%
Trades-

Technical

Shs Outstand129.10M
Shs Float126.90M
Short Float10.35%
Short Ratio6.64
Short Interest13.13M
52W High20.15 -15.91%
52W Low7.07 139.84%
Volatility5.07% 5.20%
ATR (14)0.89
RSI (14)48.52
Beta1.83
Rel Volume0.25
Avg Volume1.98M
Volume252,185

Performance

Perf Week-1.20%
Perf Month1.71%
Perf Quarter3.39%
Perf Half Y105.15%
Perf YTD44.09%
Perf Year62.62%
Perf 3Y7.52%
Perf 5Y-60.14%
Perf 10Y90.18%
Recom1.36
Target Price23.40
Prev Close16.96
Price16.94
Change %-0.09%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 06, 2026UpgradeBBTIG ResearchNeutral → Buy$28+65.2%
Apr 29, 2026UpgradeLLeerink PartnersMarket Perform → Outperform$25+47.5%
Jul 30, 2025DowngradeBBTIG ResearchBuy → Neutral
Jul 29, 2025DowngradeWWilliam BlairOutperform → Mkt Perform
May 15, 2025InitiatedGGuggenheimNeutral
Apr 30, 2025DowngradeLLeerink PartnersOutperform → Market Perform$9-46.9%
Jan 13, 2025DowngradeTThe Benchmark CompanyBuy → Hold
Dec 10, 2024InitiatedJJefferiesBuy$22+29.8%
May 01, 2024ResumedCCraig HallumBuy$26+53.4%
Dec 29, 2023ReiteratedBBTIG ResearchBuy$25 → $21+23.9%

Peers

Mkt cap
TickerCompanyMkt cap
PSNLPersonalis Inc1.73B
LHLabcorp Holdings Inc30.05B
ADPTAdaptive Biotechnologies Corp5.07B
DGXQuest Diagnostics Inc28.32B
VCYTVeracyte Inc2.01B
GHGuardant Health Inc21.30B
FLGTFulgent Genetics Inc727.81M
TEMTempus AI Inc14.82B
NTRANatera Inc46.67B
CAICaris Life Sciences Inc7.06B

Insider trading

latest 14 of 37
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Stone WarrenPres & Chief Operating OfficerOct 01 '26Option Exercise0.0017,5620198,640Oct 05 04:29 PM
Stone WarrenPres & Chief Operating OfficerAug 21 '26Option Exercise0.0028,1060192,138Aug 25 04:33 PM
Aunan Greg DChief Accounting OfficerAug 04 '26Sale16.0720,000321,4005,153Aug 06 04:02 PM
GREG AUNANOfficerAug 04 '26Proposed Sale16.0720,000321,480Aug 04 04:20 PM
JEFFREY SHERMANFormer AffliateJul 30 '26Proposed Sale15.64236,8763,704,556Jul 30 04:05 PM
TETRAULT LYNN A.DirectorJun 15 '26Sale11.105,30758,90886,115Jun 17 04:07 PM
LYNN TETRAULTDirectorJun 15 '26Proposed Sale11.155,30759,173Jun 15 04:36 PM
TETRAULT LYNN A.DirectorJun 09 '26Sale11.295,30759,91691,422Jun 11 04:10 PM
LYNN TETRAULTDirectorJun 09 '26Proposed Sale10.955,30758,112Jun 09 04:22 PM
Kenny John P.DirectorJun 01 '26Option Exercise0.005,89305,893Jun 03 07:48 PM
Williams FeliciaDirectorJun 01 '26Option Exercise0.0023,077030,237Jun 03 07:47 PM
TETRAULT LYNN A.DirectorJun 01 '26Option Exercise0.0023,077096,729Jun 03 07:47 PM
Perez David BrianDirectorJun 01 '26Option Exercise0.0023,077056,967Jun 03 07:46 PM
Kelly Michael AaronDirectorJun 01 '26Option Exercise0.0023,077067,086Jun 03 07:46 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XSMOInvesco S&P SmallCap Momentum ETFAUM: 2.74B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 206
  • NeoGenomics to Participate in Upcoming Investor Conferences (Business Wire)
  • NeoGenomics Tops Consensus But Misses The Whisper As NGS Acceleration And A Third Guidance Raise Collide With Thin Cash Conversion (Earnings Whispers)
  • NeoGenomics: Q3 Earnings Snapshot (Associated Press)
  • NeoGenomics Reports Third Quarter 2026 Results (Business Wire)
  • NeoGenomics Faces A Tough Third-Quarter Comp After Three Straight Guidance Raises (Earnings Whispers)
  • Loading…
  • NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology (Business Wire)
  • NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026 (Business Wire)
  • NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat (TIKR) -13.72%
  • NeoGenomics stock falls on CEO transition announcement (Investing.com)
  • NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan (Business Wire)
  • NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (Business Wire)
  • Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? (Stocktwits) +7.31%
  • NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-280.0700.056-0.060209.25206.711
2026Q22026-07-280.0500.0340.017201.66196.9311
2026Q12026-04-280.0100.006-0.132186.67184.5412
2025Q42026-02-170.0600.038-0.077190.17188.513
2025Q32025-10-280.0300.021-0.211187.8183.7314
2025Q22025-07-290.0300.023-0.352181.33182.6514
2025Q12025-04-290.000-0.013-0.204168.04170.5815
2024Q42025-02-180.0400.029-0.121172173.1915
2024Q32024-11-050.0500.012-0.139167.8216714
2024Q22024-07-290.030-0.003-0.148164.5161.8214
2024Q12024-04-30-0.020-0.040-0.215156.24149.8513
2023Q42024-02-200.030-0.025-0.114155.55152.5413
2023Q32023-11-060.000-0.075-0.147151.95141.6713
2023Q22023-08-08-0.050-0.114-0.194146.92137.4513
2023Q12023-05-08-0.090-0.139-0.246137.22129.2712
2022Q42023-02-23-0.060-0.165-0.182138.71129.9713

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.3100.2770.077408.83406.23
2020FY0.1500.0720.037444443.8
2021FY-0.270-0.268-0.070484.33484.65
2022FY-0.560-0.684-1.161509.73501.06
2023FY-0.120-0.174-0.701591.64588.86
2024FY0.1100.098-0.622660.57661.86
2025FY0.1200.094-0.840727.33725.65
2026FY-0.204--808.2
2027FY-0.313--888.03
2028FY-0.403--971.97
2029FY-0.690--1,029
2030FY-0.810--1,112

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-061110210.6209.7211.2
2026Q4S2026-10-291210210.6209.7211.2
2026Q4S2026-10-281200209.97207.3211.57
2026Q4S2026-10-121200209.97207.3211.57
2026Q4S2026-10-021202209.97207.3211.57
2026Q4S2026-07-291202209.94207.3211.2
2026Q4S2026-07-131200211209.7215.76
2026Q4S2026-05-261220211209.7215.76
2026Q4S2026-05-061220211209.7215.76
2026Q4S2026-05-041230211209.7215.76
2026Q4S2026-05-031330210.84208.9215.76
2026Q4S2026-04-291390210.84208.9215.76
2026Q4S2026-04-171380210.06208.1211.3
2026Q4S2026-04-151490210.07208.1211.3

Estimate history

EPS, annual-0.1380.0670.0770.037-0.07-1.161-0.701-0.622-0.843-0.2508
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.139-0.121-0.204-0.352-0.211-0.077-0.1320.017-0.059
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual240.251276.741408.83444.448484.329509.728591.643660.566727.332787.75
Period201720182019202020212022202320242025TTM
Sales, quarterly167.824172168.035181.33187.797190.17186.672201.656209.254
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual80.46394.465104.781112.075124.108126.914127.369128.145128.989129.101
Period201720182019202020212022202320242025MRQ
Shares, quarterly128.062128.145128.356128.682128.885128.989129.654127.918129.101
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue787.75727.33660.57591.64509.73484.33444.45408.83276.74
Cost of Goods Sold Incl. D&A451.77444.79403.91382.17336.48304.76278.97232.82163.00
Gross Profit335.98282.54256.65209.47173.25179.57165.48176.01113.74
Selling, General and Administrative Excl. Other382.38348.62328.35306.12323.88274.78177.87159.81101.40
Research and Development39.3337.0831.1627.3130.3321.878.038.393.00
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-46.40-66.08-71.69-96.65-150.63-95.21-12.3916.2012.34
Interest Expense3.253.756.626.911.515.087.023.716.23
Unusual Expense-8.2249.8020.4111.097.0015.64-8.864.212.30
Net Income Before Taxes-36.18-110.27-80.67-97.10-159.34-15.07-14.063.653.82
Income Taxes-3.88-2.24-1.95-9.13-15.09-6.73-18.23-4.361.18
Consolidated Net Income-32.30-108.03-78.73-87.97-144.25-8.354.178.012.64
Net Income From Continuing Operations-32.30-108.03-78.73-87.97-144.25-8.354.178.012.64
Net Income-32.30-108.03-78.73-87.97-144.25-8.354.178.016.09
EPS (Recurring)-0.30-0.57-0.51-0.64-1.120.02-0.020.110.08
EPS (Basic, Before Extraordinaries)-0.25-0.84-0.62-0.70-1.16-0.070.040.080.07
EPS (Diluted)-0.25-0.84-0.62-0.70-1.16-0.070.040.080.07
EBITDA18.801.750.85-24.07-71.42-33.1429.5052.1134.07
Non-Operating Income (Expense)5.259.3718.0517.55-0.21100.86-3.50-4.630.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense27.4432.6426.4019.4619.497.157.457.305.44
Price To Earnings Ratio------1,916.01405.69196.72
Price To Sales Ratio3.002.073.163.432.258.4513.547.414.17
Gross Margin42.6538.8538.8535.4033.9937.0837.2343.0541.10
Operating Margin-5.89-9.09-10.85-16.34-29.55-19.66-2.793.964.46
Net Margin-4.10-14.85-11.92-14.87-28.30-1.720.941.962.20
Shares Outstanding129.10128.99128.15127.37126.91124.11112.08104.7894.47
Market Capitalization2,194.442,194.442,115.392,062.401,167.044,200.925,977.863,053.931,185.55

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue209.25201.66186.67190.17187.80181.33168.03172.00
Cost of Goods Sold Incl. D&A115.69112.80108.83114.46110.37107.3998.24103.10
Gross Profit93.5788.8677.8475.7177.4273.9469.7968.90
Selling, General and Administrative Excl. Other100.3199.1496.0986.8591.6093.2394.6484.19
Research and Development9.8610.769.539.188.699.0210.187.97
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.74-10.28-18.24-11.14-14.18-19.29-24.84-15.30
Interest Expense1.270.780.600.600.600.931.621.62
Unusual Expense1.20-11.690.002.2712.8419.742.983.10
Net Income Before Taxes-8.021.83-17.58-12.41-26.39-45.82-25.66-16.13
Income Taxes-0.47-0.41-0.47-2.520.74-0.720.27-0.80
Consolidated Net Income-7.552.24-17.11-9.88-27.13-45.09-25.92-15.32
Net Income From Continuing Operations-7.552.24-17.11-9.88-27.13-45.09-25.92-15.32
Net Income-7.552.24-17.11-9.88-27.13-45.09-25.92-15.32
EPS (Recurring)-0.05-0.05-0.13-0.06-0.14-0.24-0.19-0.10
EPS (Basic, Before Extraordinaries)-0.060.02-0.13-0.08-0.21-0.35-0.20-0.12
EPS (Diluted)-0.060.02-0.13-0.08-0.21-0.35-0.20-0.12
EBITDA9.455.93-1.835.252.26-2.02-7.112.89
Non-Operating Income (Expense)1.191.201.261.611.23-5.863.793.90
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.986.497.616.358.149.658.506.58
Price To Sales Ratio3.002.491.282.081.401.361.803.17
Gross Margin44.7244.0641.7039.8141.2340.7841.5440.06
Operating Margin-3.22-5.10-9.77-5.86-7.55-10.64-14.78-8.89
Net Margin-3.611.11-9.16-5.20-14.45-24.87-15.43-8.91
Shares Outstanding129.10127.92129.65128.99128.89128.68128.36128.15
Market Capitalization2,194.441,899.79963.211,521.60997.26940.761,219.092,115.39

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments159.62386.84415.20437.99515.39296.26173.029.8112.82
Short Term Receivables159.74151.94132.96122.51114.47108.4995.2476.9260.43
Inventories28.5726.7524.1624.2823.3929.5314.408.657.47
Other Current Assets28.2230.2824.4920.5228.2514.468.078.295.15
Total Current Assets376.15595.81596.81605.29681.51448.73290.74103.6785.88
Net Property, Plant & Equipment163.28173.69183.78198.61211.66131.6690.6860.8936.50
Total Investments and Advances0.000.000.000.000.0051.470.000.500.00
Long-Term Note Receivable--0.000.030.240.490.15--
Intangible Assets810.87862.45895.89931.03969.44331.74325.24337.92221.18
Deferred Tax Assets-----57.58---
Other Assets9.536.094.745.086.9324.242.692.040.89
Total Assets1,359.831,638.041,681.231,740.031,869.781,045.91709.51505.01344.45
Short Term Debt Incl. Current Port. of LT Debt4.78204.165.616.658.027.8113.8114.178.99
Accounts Payable23.0921.6120.3320.5117.9224.9619.5717.7810.45
Other Current Liabilities60.4375.4870.3662.7761.2940.4130.5228.9817.03
Total Current Liabilities88.30301.2496.3089.9387.2373.1863.9060.9236.47
Long Term Debt404.68401.18606.07604.27604.84211.38119.0698.1396.44
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities18.2221.5124.2934.7555.4862.9915.5722.466.69
Other Liabilities12.0711.7713.0313.0513.954.063.573.060.28
Total Liabilities523.27735.70739.69742.01761.50351.62202.10184.57139.88
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0032.62
Common Equity836.56902.34941.54998.021,108.28694.29507.41320.44171.96
Total Shareholders Equity836.56902.34941.54998.021,108.28694.29507.41320.44204.58
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity836.56902.34941.54998.021,108.28694.29507.41320.44204.58
Total Liabilities & Stockholders Equity1,359.831,638.041,681.231,740.031,869.781,045.91709.51505.01344.45
Book Value Per Share6.497.047.397.868.936.194.843.392.14
Tangible Book Value Per Share0.200.310.360.531.123.231.74-0.19-0.61
Full-Time Employees2,5002,2002,1002,1002,0001,7001,7001,5001,000
Price to Book Ratio2.732.322.171.153.828.696.043.724.20
Return on Assets-7.21-4.74-5.14-7.99-0.570.481.320.62-0.12
Return on Equity-12.42-8.54-9.07-13.70-0.930.691.931.00-0.20
Return on Invested Capital-8.70-6.04-5.68-9.00-0.490.461.280.63-0.13
Quick Ratio3.941.895.956.467.545.734.321.562.15
Current Ratio4.261.986.206.737.816.134.551.702.35

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-32.30-108.03-78.73-87.97-144.25-8.354.178.012.64
Depreciation65.2167.8272.5581.8279.2062.0741.8935.9121.73
Other Funds (Non Cash)32.6077.5345.8329.6930.75-75.8417.1511.887.90
Funds from Operations65.5137.3339.6523.54-50.39-22.1263.2155.7932.27
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-61.23-32.09-32.63-25.49-15.60-4.60-61.75-32.4212.51
Cash from Operating Activities4.285.237.02-1.95-65.99-26.721.4623.3744.79
Capital Expenditures-32.86-27.01-41.06-28.75-30.89-64.14-29.10-20.03-14.31
Net Assets From Acquisitions0.00-6.450.000.000.00-419.40-37.000.00-125.38
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.40-
Purchase or Sale of Investments0.0019.5653.92105.4619.31-148.82-93.340.000.00
Purchase of Investments0.00-0.500.00-6.76-97.61-211.79-98.700.000.00
Sale Or Maturity of Investments0.0020.0653.92112.22116.9262.975.360.000.00
Other Uses-0.68-0.500.000.000.000.000.000.000.00
Other Sources2.072.070.000.0012.100.000.000.000.00
Cash from Investing Activities-31.47-12.3412.8676.710.52-632.37-159.44-19.63-139.69
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-7.530.964.654.6212.59423.21147.60171.9894.00
Repurchase of Common Pref Stock-25.000.000.000.000.000.000.000.00-50.10
Sale of Common Pref Stock17.480.964.654.6212.59423.21147.60171.98144.09
Proceedsfrom Stock Options3.030.964.654.6212.59423.21147.60171.98144.09
Issuance or Reduction of Debt, Net42.09-201.250.00-0.07-0.76331.3691.31-12.51-2.04
Change in Long Term Debt-159.16-201.250.00-0.07-0.76331.3691.31-12.51-2.04
Issuance of Long Term Debt304.980.000.000.000.00334.41194.4798.9429.42
Reduction of Long Term Debt-464.14-201.250.00-0.07-0.76-3.05-103.16-111.45-31.46
Net Financing Active Other Cash Flow-32.240.000.000.000.00-29.29-3.320.000.00
Other Financing Activities Uses-32.320.000.000.000.00-29.29-3.320.000.00
Cash from Financing Activities2.32-200.294.654.5511.83725.28235.60159.4791.96
Exchange Rate Effect------0.000.00-0.07
Net Change in Cash-24.84-207.3924.5279.31-53.6566.1977.62163.21-3.01
Free Cash Flow-28.58-21.78-34.04-30.70-96.88-90.86-27.643.3430.48
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Price to Free Cash Flow-------907.4137.89
Deferred Taxes & Investment Tax Credit-0.000.000.00-16.100.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments139.28145.54146.14159.62164.12163.69
Short Term Receivables213.41175.87167.82159.74155.80153.62
Inventories25.5027.1429.8428.5728.4634.17
Other Current Assets31.7032.7029.7028.2233.9140.87
Total Current Assets409.89381.24373.51376.15382.29392.35
Net Property, Plant & Equipment170.21166.20160.36163.28165.62168.33
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets787.62795.26802.89810.87818.51825.94
Other Assets9.199.549.779.538.377.33
Total Assets1,376.921,352.241,346.531,359.831,374.781,393.95
Short Term Debt Incl. Current Port. of LT Debt6.005.434.834.784.514.05
Accounts Payable32.9220.9525.9023.0922.6127.49
Other Current Liabilities77.2579.5053.8660.4370.7568.58
Total Current Liabilities116.17105.8884.5988.3097.87100.12
Long Term Debt443.14442.94403.70404.68405.80407.71
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities16.1016.8217.4518.2220.8519.98
Other Liabilities0.870.8612.0312.0711.9812.10
Total Liabilities576.28566.51517.77523.27536.49539.91
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity800.64785.73828.76836.56838.29854.04
Total Shareholders Equity800.64785.73828.76836.56838.29854.04
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity800.64785.73828.76836.56838.29854.04
Total Liabilities & Stockholders Equity1,376.921,352.241,346.531,359.831,374.781,393.95
Book Value Per Share6.206.146.396.496.506.64
Tangible Book Value Per Share0.10-0.070.200.200.150.22
Full-Time Employees---2,500--
Price to Book Ratio2.732.281.141.811.161.06
Return on Assets-2.35-3.78-6.73-7.21-7.52-6.85
Return on Equity-3.94-6.33-11.56-12.42-12.99-11.76
Return on Invested Capital-0.610.18-1.39-0.80-2.18-3.57
Quick Ratio3.313.344.063.943.623.58
Current Ratio3.533.604.424.263.913.92

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-7.552.24-17.11-9.88-27.13-45.09
Depreciation16.1916.2116.4116.3916.4417.26
Other Funds (Non Cash)11.15-0.7811.7610.4719.8034.15
Funds from Operations19.7917.6711.0616.989.116.32
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-28.682.29-19.20-15.64-0.2314.01
Cash from Operating Activities-8.8819.96-8.141.348.8820.33
Capital Expenditures-11.77-8.22-5.00-7.87-8.31-6.32
Net Assets From Acquisitions0.000.000.000.00-0.46-5.99
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.008.503.00
Purchase of Investments0.000.000.000.00-0.500.00
Sale Or Maturity of Investments0.000.000.000.009.003.00
Other Uses-0.07-0.100.00-0.500.000.00
Other Sources0.000.000.002.070.000.00
Cash from Investing Activities-11.85-8.32-5.00-6.30-0.28-9.31
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock14.02-21.64-0.340.430.77-1.18
Repurchase of Common Pref Stock0.00-25.000.000.000.000.00
Sale of Common Pref Stock14.023.36-0.340.430.77-1.18
Proceedsfrom Stock Options0.852.09-0.340.430.77-1.18
Issuance or Reduction of Debt, Net0.8641.230.000.000.00-201.25
Change in Long Term Debt0.8641.230.00-201.250.000.00
Issuance of Long Term Debt0.86304.120.000.000.000.00
Reduction of Long Term Debt0.00-262.890.00-201.250.000.00
Net Financing Active Other Cash Flow-0.40-31.840.000.000.000.00
Other Financing Activities Uses-0.40-31.910.000.000.000.00
Cash from Financing Activities14.47-12.24-0.340.430.77-202.43
Net Change in Cash-6.26-0.60-13.47-4.509.39-191.47
Free Cash Flow-20.6611.74-13.14-6.530.5714.01

Revenue breakdown

Client Direct Billing2024: 475.44M 2025: 518.84M
Commercial Insurance2024: 99.84M 2025: 117.51M
Medicare And Other Governmental2024: 84.60M 2025: 90.87M
Self Pay Services2024: 681.00K 2025: 114.00K
United States2024: 660.57M 2025: 727.33M
Total Services-Testing Laboratories revenue2024: 660.57M 2025: 727.33M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.35%13.1M126.9M2.05M
2026-10-1511.28%14.2M126.0M2.36M
2026-09-3011.23%14.2M126.0M2.35M
2026-09-1513.26%16.7M126.0M2.83M
2026-08-3112.51%15.8M126.0M2.81M
2026-08-1412.60%15.9M126.1M2.75M
2026-07-3113.28%15.4M116.1M2.70M
2026-07-1510.77%13.8M127.8M2.65M
2026-06-309.09%11.6M127.8M2.53M
2026-06-156.62%8.5M127.8M1.88M
2026-05-296.64%8.5M127.8M1.93M
2026-05-156.74%8.6M128.0M2.08M
2026-04-307.46%9.5M128.0M2.10M
2026-04-156.17%7.9M127.9M1.81M
2026-03-315.95%7.6M127.9M1.87M
2026-03-136.54%8.4M127.9M1.90M
2026-02-276.61%8.5M127.9M1.84M
2026-02-136.95%8.9M127.9M1.84M
2026-01-308.14%10.0M123.1M1.97M
2026-01-156.57%8.1M123.1M2.46M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.0014.8017.609.800.0000.000.000.996-0.0160.000
call2.0013.8016.608.9622.2882.000.000.994-0.0170.000
call3.0012.2016.108.0619.1501.000.000.992-0.0180.001
call4.0011.8014.507.4611.5751.000.000.959-0.1160.002
call5.0010.2014.100.0012.7450.000.000.948-0.1180.003
call6.009.8012.600.008.8040.000.000.938-0.1190.003
call7.008.2011.403.507.37410.000.000.925-0.1180.004
call8.008.409.902.515.1480.000.000.914-0.1160.004
call9.006.2010.100.006.5540.000.000.899-0.1130.005
call10.005.209.105.486.2655.000.000.884-0.1090.005
call11.005.407.405.855.3901630.000.865-0.1050.006
call12.003.806.404.803.9301200.000.844-0.1000.006
call13.003.005.203.003.0131.000.000.803-0.1090.007
call14.002.354.203.202.5411100.000.740-0.1460.009
call15.000.904.002.162.94449.000.000.695-0.1320.009
call16.000.852.401.001.82839.000.000.634-0.1160.010
call17.000.401.650.601.57386.000.000.551-0.1020.011
call18.000.051.150.271.4801010.000.455-0.0940.011
call19.000.000.300.250.89674.000.000.231-0.0410.008
call20.000.000.150.150.88955.000.000.134-0.0290.006
call21.000.000.500.771.0157.000.000.119-0.0300.005
call22.000.001.750.101.2251.000.000.104-0.0330.005
call23.000.000.950.001.3240.000.000.097-0.0340.005
call24.000.001.150.461.5083.000.000.089-0.0360.004
call25.000.002.150.061.63525.000.000.083-0.0370.004
call26.000.000.750.001.7550.000.000.079-0.0380.004
call27.000.001.750.001.8690.000.000.075-0.0390.004
call28.000.001.150.001.9760.000.000.072-0.0400.004
call29.000.001.750.002.0790.000.000.069-0.0410.004
call30.000.002.150.002.1630.000.000.067-0.0420.003
call31.000.000.750.002.2690.000.000.065-0.0430.003
call32.000.000.950.002.3580.000.000.063-0.0430.003
call33.000.000.750.002.4360.000.000.061-0.0440.003
call34.000.000.750.002.4810.000.000.060-0.0440.003
call35.000.000.950.002.6040.000.000.058-0.0450.003
put1.000.000.050.008.9510.000.00-0.004-0.0150.000
put2.000.000.050.006.5860.000.00-0.006-0.0160.000
put3.000.000.050.005.3100.000.00-0.008-0.0160.001
put4.000.002.150.008.8260.000.00-0.041-0.1150.002
put5.000.001.750.007.4970.000.00-0.052-0.1180.003
put6.000.001.750.006.4690.000.00-0.063-0.1180.003
put7.000.002.150.205.6292.000.00-0.074-0.1170.004
put8.000.000.950.154.9188.000.00-0.087-0.1150.004
put9.000.002.150.154.2990.000.00-0.101-0.1120.005
put10.000.001.600.133.7481900.00-0.116-0.1080.005
put11.000.000.950.453.2581.000.00-0.134-0.1040.006
put12.000.000.750.052.7880.000.00-0.156-0.0980.006
put13.000.000.950.172.6481.000.00-0.196-0.1080.007
put14.000.002.200.333.0447.000.00-0.258-0.1450.009
put15.000.001.650.352.53280.000.00-0.305-0.1310.009
put16.000.101.750.262.1442130.00-0.366-0.1150.010
put17.000.252.000.851.87425.000.00-0.449-0.1000.011
put18.000.052.751.332.0453.000.00-0.540-0.0920.011
put19.000.104.002.352.5675.000.00-0.769-0.0390.008
put20.002.254.400.002.4400.000.00-0.860-0.0250.006
put21.003.004.500.001.5410.000.00-0.884-0.0290.005
put22.003.805.900.002.2100.000.00-0.896-0.0310.005
put23.004.407.500.003.2260.000.00-0.902-0.0310.005
put24.006.107.600.002.2670.000.00-0.911-0.0330.004
put25.007.108.600.002.4140.000.00-0.916-0.0340.004
put26.008.109.600.002.5070.000.00-0.921-0.0350.004
put27.007.9011.800.004.0370.000.00-0.925-0.0360.004
put28.008.9012.400.003.7590.000.00-0.928-0.0370.004
put29.009.9013.800.004.3250.000.00-0.931-0.0380.004
put30.0011.4014.800.004.5350.000.00-0.933-0.0380.003
put31.0011.9015.800.004.5830.000.00-0.935-0.0390.003
put32.0013.4016.200.004.2740.000.00-0.937-0.0390.003
put33.0013.9017.800.004.8180.000.00-0.939-0.0400.003
put34.0014.9018.800.004.9280.000.00-0.940-0.0410.003
put35.0016.3019.100.004.2810.000.00-0.941-0.0410.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-288-KCurrent report2026-10-28SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-25S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-118-KCurrent report2026-08-07SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-07-30SCHEDULE 13G/ASEC
2026-07-30144Filing for proposed sale of securities under Rule 144.SEC
2026-07-30SCHEDULE 13GSEC
2026-07-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-288-KCurrent report2026-07-28SEC
2026-07-228-K/A2026-07-20SEC
2026-07-208-KCurrent report2026-07-20SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-253Initial statement of beneficial ownership of securities2026-06-23SEC
2026-06-258-KCurrent report2026-06-23SEC
2026-06-228-KCurrent report2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-06-15144Filing for proposed sale of securities under Rule 144.SEC
2026-06-158-KCurrent report2026-06-15SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800321.40K1
2026-070000
2026-0600118.82K2
2026-050000
2026-040000
2026-030000
2026-020000
2026-0100276.68K1
2025-120000
2025-1100250.99K1

Institutional holders

Manager% owned
BlackRock, Inc.16.03%
First Light Asset Management, LLC9.43%
FIRST TRUST ADVISORS LP7.77%
Greenhouse Funds LLLP6.58%
VANGUARD PORTFOLIO MANAGEMENT LLC6.19%
VANGUARD CAPITAL MANAGEMENT LLC4.43%
STATE STREET CORP4.12%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.3.87%
BRAIDWELL LP3.78%
SCHRODER INVESTMENT MANAGEMENT GROUP3.34%

Funds

Fund% owned
First Trust NYSE Arca Biotechnology Index Fund7.58%
iShares Convertible Bond ETF6.23%
iShares Core S&P Small-Cap ETF6.03%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
Nomura Small Cap Core Fund3.18%
iShares Russell 2000 ETF2.62%
VANGUARD SMALL-CAP INDEX FUND2.29%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.32%
VANGUARD EXTENDED MARKET INDEX FUND1.14%
Fidelity Small Cap Index Fund1.12%

OakChart. NEO. Cached 15 minutes.